Company Filing History:
Years Active: 2014
Title: Richard Benn Abegania Ventura: Innovator in Beta Catenin Pathway Modulation
Introduction
Richard Benn Abegania Ventura is a notable inventor based in Daly City, California. He has made significant contributions to the field of biotechnology, particularly in understanding the beta catenin pathway. His work has implications for therapeutic targets related to disorders associated with defective beta catenin function.
Latest Patents
Richard holds a patent titled "PLKS as Modifiers of the Beta Catenin Pathway and Methods of Use." This patent identifies human PLK genes as modulators of the beta catenin pathway. The methods outlined in the patent provide a framework for identifying agents that can modulate the activity of PLK, which could lead to advancements in treating various disorders.
Career Highlights
Richard is currently employed at Exelixis, Inc., a company known for its focus on innovative cancer therapies. His work at Exelixis has allowed him to collaborate with other talented professionals in the field, enhancing the research and development of new therapeutic strategies.
Collaborations
Some of Richard's coworkers include Helen Louise Francis-Lang and Christopher Winter. Their collective expertise contributes to the innovative environment at Exelixis, fostering advancements in biotechnology.
Conclusion
Richard Benn Abegania Ventura's contributions to the understanding of the beta catenin pathway highlight his role as an influential inventor in biotechnology. His patent work and collaborations continue to pave the way for potential therapeutic advancements.